C4 Therapeutics has begun its Phase 2 MOMENTUM trial of cemsidomide, an oral IKZF1/3 degrader, in combination with dexamethasone for patients with relapsed or refractory multiple myeloma. The first patient was dosed on February 23 2026, marking the first clinical exposure of the drug in a multi‑center setting.
The MOMENTUM study is a single‑arm, open‑label trial that will enroll roughly 100 patients and will evaluate the safety, tolerability, pharmacokinetics and anti‑myeloma activity of a 100 µg dose of cemsidomide. The design follows encouraging Phase 1 data that reported a 53 % overall response rate at the same dose and a differentiated safety profile, positioning the drug for potential accelerated approval through two parallel development pathways.
C4’s strategy is to establish cemsidomide as a foundational oral therapy for multiple myeloma. The drug is built on the company’s TORPEDO platform, which enables the design of targeted protein degraders. C4 plans to pursue accelerated approval in both fourth‑line or later and second‑line or later settings, and a Phase 1b combination with the bispecific antibody elranatamab is slated to begin in Q2 2026. The trial places cemsidomide in direct competition with established IKZF1/3 degraders such as pomalidomide and lenalidomide.
The initiation of the Phase 2 study moves cemsidomide closer to regulatory review and validates the TORPEDO platform’s ability to generate clinically relevant degraders. For C4, the milestone supports the broader pipeline and provides a potential market entry point for an oral, convenient treatment option. While the company’s Q1 2026 financials showed a decline in revenue and continued operating losses, its liquidity remains strong, giving it the resources to fund ongoing development.
The announcement was well received by investors, reflecting confidence in the trial’s potential to advance cemsidomide toward accelerated approval and to strengthen C4’s position in the multiple myeloma market.
Len Reyno, Chief Medical Officer, said the Phase 2 launch “builds upon the compelling anti‑myeloma activity and differentiated safety profile established in Phase 1, and is a critical step for cemsidomide to become a foundational therapy for patients who need a safe, oral, and convenient treatment option.”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.